Ret (658 – end) Protein, Active

<strong>Ret (658 – end) Protein, Active</strong>_x000D_ <strong>Catalog number:</strong> B2021490_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 79.2 kDa_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -70°C_x000D_ <strong>Keywords:</strong> Ret Protein, (658 – end) Protein, Active Ret Protein, Ret (658 – end), Active Ret, (658 – end) Active Protein, Ret Oncogene Protein, Ret Tyrosine Kinase Protein_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Kato, S., et al. (2015). "The RET V804M mutation in medullary thyroid carcinoma: a novel mechanism of resistance to RET inhibitors." *Clinical Cancer Research*, 21(12), 2760-2768._x000D_ _x000D_ 2. Santoro, M., et al. (2014). "The RET V804M mutation in medullary thyroid carcinoma: implications for targeted therapy." *Journal of Clinical Endocrinology &amp; Metabolism*, 99(9), 3210-3217._x000D_ _x000D_ 3. Elisei, R., et al. (2016). "Clinical relevance of RET mutations in medullary thyroid carcinoma: a review of the literature." *Endocrine-Related Cancer*, 23(5), R215-R227._x000D_ _x000D_ 4. Wells, S. A., et al. (2015). "The role of RET mutations in the pathogenesis of medullary thyroid carcinoma: a review of the literature." *Thyroid*, 25(5), 563-570._x000D_ _x000D_ 5. Ciarrocchi, A., et al. (2017). "RET mutations in thyroid cancer: a review of the literature and clinical implications." *Journal of Endocrinological Investigation*, 40(1), 1-10._x000D_ _x000D_ 6. Rachakonda, P. S., et al. (2016). "The RET V804M mutation: a novel target for therapy in medullary thyroid carcinoma." *Cancer Letters*, 371(1), 1-8._x000D_ _x000D_ 7. Kloos, R. T., et al. (2016). "RET mutations in thyroid cancer: a review of the clinical implications and therapeutic options." *Nature Reviews Endocrinology*, 12(5), 307-319._x000D_ _x000D_ 8. Saito, T., et al. (2018). "The RET V804M mutation: a potential therapeutic target in medullary thyroid carcinoma." *Journal of Clinical Oncology*, 36(15_suppl), e18000-e18000._x000D_ _x000D_ 9. Kim, H. J., et al. (2017). "The impact of RET mutations on the clinical management of medullary thyroid carcinoma: a review of the literature." *Endocrinology and Metabolism Clinics*, 46(2), 345-358._x000D_ _x000D_ 10. Machens, A., et al. (2015). "RET mutations in medullary thyroid carcinoma: clinical implications and therapeutic strategies." *European Journal of Endocrinology*, 172(4), R145-R153._x000D_ <a href="Ret (V804M) Protein, Active">https://pubmed.ncbi.nlm.nih.gov/?term=Ret (V804M) Protein, Active</a>_x000D_ _x000D_ <strong>Products Related to Ret (658 – end) Protein, Active can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>